Fig. 2

Comparison of serum DIDO1-, CPSF2-, and FOXJ2-Ab levels between HDs and patients with TIA or AIS. GST-DIDO1:1-275 (a), biotinylated FOXJ2 peptide (bFOXJ2-426) (d), and biotinylated CPSF2 peptide (bCPSF2-607) (g) were used as the antigens. The AlphaLISA-determined serum antibody levels after subtraction of the levels against those of control GST are shown as box-whisker plots displaying the 10th, 20th, 50th, 80th, and 90th percentiles. P values were calculated by the Kruskal–Wallis test. ^*P < 0.05, ^**P < 0.01, ^***P < 0.001. The serum numbers of HDs, TIA, and AIS were 285, 92, and 464, respectively. The other information including total (male/female) numbers, average values, SDs, cutoff values, positive numbers, positive rates (%), and P values is summarized and shown in Table 2. Receiver operating characteristic curve (ROC) analysis was performed to assess the ability of DIDO1-Abs (b, c), FOXJ2-Abs (e, f), and CPSF2-Abs (h, i) to detect TIA and AIS. The numbers in the figures indicate the cutoff values for marker levels, and the numbers in parentheses indicate the sensitivity (left) and specificity (right). The areas under the curve (AUC), and 95% confidence intervals (CIs) are also shown in Table 5